Investor Connect: Akhilesh Pathipati of MVM Partners

Investor Connect: Akhilesh Pathipati of MVM Partners

February 8, 2021 by investor

In this episode, Hall welcomes Akhilesh Pathipati, Partner at MVM Partners.

Headquartered in Boston, Massachusetts, MVM Partners has been a life science investment fund for more than 20 years and invests broadly across the healthcare sector, including medical technology, specialty pharmaceuticals, diagnostics, life science tools, and digital health.

MVM has a global perspective on healthcare and maintains offices in Boston and London. Current MVM portfolio companies are headquartered in the US and Europe.

Prior to joining the firm, Akhilesh practiced medicine as a resident at Beth Israel Deaconness Medical Center and Signature Healthcare Brockton Hospital. In addition, his research on healthcare systems has led to more than a dozen scientific publications and 50 articles in the popular press, including in The Washington Post and Scientific American.

Akhilesh received an MD at the Stanford School of Medicine and an MBA at the Stanford Graduate School of Business. He also holds an AB magna cum laude with highest honors from Harvard University.

Akhilesh shares some of the challenges investors and startups face in the sector. He also advises investors and entrepreneurs.

You can visit MVM Partners at www.mvm.com, and via LinkedIn at www.linkedin.com/company/mvm-life-science-partners-llp/  

Akhilesh can be contacted via email at ap@mvm.com, and via LinkedIn at www.linkedin.com/in/akhileshpathipati/.  

For a full transcript, click here.

Music courtesy of Bensound.



Copyright (c) 2021, Hall Martin and investorconnect.org. All rights reserved.

Disclaimer:
Hall T Martin is the director of Investor Connect, which is a 501(c)(3) nonprofit dedicated to the education of investors for early-stage funding. All opinions expressed by Hall and podcast guests are solely their own opinions and do not reflect the opinion of Investor Connect. This podcast is for informational purposes only and should not be relied upon for the basis of investment decisions.

Tags: